IQ-AI Limited Agreement with St. Jude Children's Hospital (0858S)
November 11 2021 - 3:52AM
UK Regulatory
TIDMIQAI
RNS Number : 0858S
IQ-AI Limited
11 November 2021
11 November 2021
IQ-AI Ltd
("IQ-AI" or the "Company")
Imaging Biometrics and St. Jude Children's Hospital Enter
Agreement
IB Zero G(TM) Technology May Benefit Imaging in Paediatric
Patients
Milwaukee - 11 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB:
IQAIF), a developer of medical image processing platforms that have
led to effective therapeutic strategies for brain tumor and other
patients, and St. Jude Children's Hospital (Memphis, TN), have
entered into a Data Use Agreement. The Agreement is a specific type
of agreement required under the Health Insurance Portability and
Accountability Act (HIPPA) Privacy Rule. It will provide Imaging
Biometrics (IB) access to paediatric imaging datasets for use in
the development of its patented, artificial intelligence (AI)
technology, IB Zero G.
St. Jude Children's Hospital is the only National Cancer
Institute (NCI)-designated Comprehensive Care Centre devoted solely
to children. It has received the NCI's highest ranking of
"exceptional" and has treated children from all 50 US states and
from around the world.
Through this Agreement, IB will have access to a wide array of
magnetic resonance (MR) datasets acquired in children of all ages.
Diverse and accurately labelled (annotated) data are critical for
developing and refining AI models. High quality data enables AI
models to accurately analyze new, incoming, real-world image
datasets. IB Zero G will use this data to generate synthetic
contrast-enhanced images for paediatric neuro examinations.
Gadolinium Based Contrast Agents (GBCAs) have been used
clinically in MRI examinations for decades and provide invaluable
diagnostic information. In 2006, safety concerns were raised for
GBCA use in patients due to the causative effect in a condition
called nephrogenic systemic fibrosis (NSF). Since then, the
awareness and understanding about GBCA use has escalated worldwide.
More recently, it was found that repeated exposure of GBCAs result
in its retention throughout the body. While the long-term adverse
side effects are not known, the detrimental concerns for critical
periods of life and especially on rapidly developing bone or brain,
remain.
"This Agreement will accelerate the development and
commercialization of IB Zero G," said Trevor Brown CEO of IQAI
"Avoiding the use of GBCAs while preserving the diagnostic quality
on paediatric images will help clinicians address concerns relating
to GBCA retention and ultimately provide better care," he
added.
IQAI is preparing to submit an FDA 510(k) application for IB
Zero G late Q1 2022.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Imaging Biometrics, LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON: IQAI)
(OTCQB: IQAIF), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat
disease with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent and automated software
plug-ins which can extend the base functionality of workstations,
imaging systems, PACS, or medical viewers. By design, IB's advanced
visualisation software seamlessly integrates into routine
workflows. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDGIBDBCSBDGBB
(END) Dow Jones Newswires
November 11, 2021 03:52 ET (08:52 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2023 to Apr 2024